In vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines

Basit Öğe Kaydı
dc.contributor.authorYurt Lambrecht F.
dc.contributor.authorDurkan K.
dc.contributor.authorÖzgür A.
dc.contributor.authorGündüz C.
dc.contributor.authorAvci C.B.
dc.contributor.authorSusluer S.Yi.
dc.date.accessioned2019-10-27T08:23:44Z
dc.date.available2019-10-27T08:23:44Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractBombesin and its derivatives exhibit a high affinity for gastrin-releasing peptide receptor (GRPr), which is over-expressed in a variety of human cancers (prostate, pancreatic, lung, etc.). The aim of this study was to investigate the in vitro potential of the hydrazinonicotinamide (HYNIC)-Q-Litorin. 99mTc labeling was performed by using different co-ligands: tricine and ethylenediamine diacetic acid (EDDA). The radiochemical stability of radiolabeled peptide conjugates was checked at room temperature and in cysteine solution up to 24 h. The in vitro cell uptake of 99mTc-EDDA-HYNIC-Q- Litorin and 99mTc-tricine-HYNIC-Q-Litorin were evaluated on pancreatic tumor and control cell lines. Optimum specific activity and incubation time were determined for all the cell lines. The results showed that the cell uptake of the radiolabeled peptide conjugates in tumor cell lines were higher than in the control cell line. The findings of this study indicated the need for further development of in vivo study as a radiopharmaceutical for pancreatic tumor imaging. © 2013 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.en_US
dc.description.sponsorship2009 BIL 025 108S200en_US
dc.description.sponsorshipThe authors gratefully acknowledge the financial support received from the Scientific and Technological Research Council of Turkey, Scientific Project (108S200) and Ege University Science-Technology Application and Research Center (2009 BIL 025). The authors have declared no conflict of interest. --en_US
dc.identifier.doi10.3109/1061186X.2012.757772en_US
dc.identifier.endpage388en_US
dc.identifier.issn1061-186X
dc.identifier.issue4en_US
dc.identifier.pmid23301856en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage383en_US
dc.identifier.urihttps://doi.org/10.3109/1061186X.2012.757772
dc.identifier.urihttps://hdl.handle.net/11454/26475
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Drug Targetingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject99mTc-EDDA/tricine-HYNIC-Q-Litorinen_US
dc.subjectBombesin like peptideen_US
dc.subjectHYNIC-Q-Litorinen_US
dc.subjectPancreatic tumoren_US
dc.titleIn vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell linesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu